Kinesin family member 2C (KIF2C/MCAK) is a novel marker for prognosis in human gliomas.

OBJECTIVE:Gliomas are a group of center nervous system tumors of glial origin. Most are characterized by diffuse infiltrative growth in the surrounding brain. Patients almost always ultimately die from their disease. The drastically increased knowledge about the molecular abnormalities, these are linked with tumor grade and patient prognosis. The aim of this study was to examine the role of KIF2C and AURKB as prognostic factors in gliomas. MATERIALS AND METHODS:A total 40 tumor samples and 6 normal brain tissue samples were collected. Biomarker KIF2C and AURKB were tested by qRT-PCR. Using Western blot validate the results. RESULTS:We found that KIF2C and AURKB genes were higher expression in glioma samples when were compared with normal brain tissues. KIF2C and AURKB expression were associated with histopathological grades. We found that KIF2C as a potential independent prognostic marker for patient with glioma by Cox analysis. CONCLUSION:The expression level of KIF2C mRNA could be a potential independent marker to evaluate patient prognosis.

KEYWORDS: {{ getKeywords(articleDetailText.words) }}